Episode Details

In his weekly clinical update, Dr. Griffin discusses Merck’s RSV preventative monoclonal antibody Clesrovimab before reviewing the recent statistics on SARS-CoV-2 infection, if previous SARS-COV-2 infections predict the outcome of subsequent infections, if using COVID rapid diagnostic tests is cost effective, if the protein based vaccine NVX-CoV2327 elicits a durable immune response, if combination treatment of vaccine and antiviral drugs effectively protect against hospitalization, where to find PEMGARDA, what do when healthcare workers succumb to SARS-CoV-2 infection, and how COVID-19 may alter the cognitive trajectories of older patients.

Become a patron of TWiV!

• Clesrovimab, RSV preventative monoclonal antibody for infants (Merck)
• COVID-19 national trend (CDC)
• COVID-19 deaths (CDC)
• Characterizing SARS-CoV-2 reinfections and long COVID (Communications Medicine)
• Cost-effectiveness of COVID rapid diagnostic tests (PLoS Medicine)
• NVX-CoV2373 against pre-Delta and Delta strains of COVID-19 little evidence of waning immune response (CID)
• Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization(CID)
• Pemgarda infusion center locator (Pemgarda)
• Respiratory virus guidance (CDC)
• Early phase of SARS-CoV-2 infection (COVID.gov)
• NIH COVID-19 treatment guidelines (NIH)
• Infectious Disease Society guidelines for treatment and management (ID Society)
• Drug interaction checker (University of Liverpool)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendation for immunocompromised (ID Society)
• What do when your 

  Listen Now